The Etanercept registry, established in 2004, collects detailed information on the effectiveness and safety of Etanercept in children with Juvenile Idiopathic Arthritis. A parallel group of children with Juvenile Idiopathic Arthritis treated with Methotrexate is also being recruited in order to compare side effects and long term outcomes between the two treatment groups. The study, previously known as the Biologics and New Drugs Register, moved to The University of Manchester to sit among the other national rheumatic disease biologic registers.
If you are an NHS clinician, health professional or research network staff with a recruitment query about a child or for more information about the register in juvenile idiopathic arthritis, contact Dr Emily Sutton.
The University of Manchester also oversees the running of the Biologics for Children with Rheumatic Diseases (BCRD) study, which was set up in 2010 and recruits children and young people with JIA who are starting any biologic or biosimilar drug other than Enbrel. Further details can be obtained from Dr Katy Mowbray, the study co-ordinator.
Collectively, there are over 2,500 participants in these two studies, which makes it one of the largest groups of children and young people involved in research about JIA in the world.